Furthermore, elevated SCARB2 expression was particularly evident in patients with IDH wildtype status (Figure 5B; p < 0.01), except for WHO grade II and III gliomas (Figure 5E; p < 0.05, p < 0.01). Here, SCARB2 is linked to central nervous system cancer.